<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122719</url>
  </required_header>
  <id_info>
    <org_study_id>C21002</org_study_id>
    <nct_id>NCT01122719</nct_id>
  </id_info>
  <brief_title>Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen</brief_title>
  <acronym>BEST</acronym>
  <official_title>The Best Trial - Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CID - Carbostent &amp; Implantable Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Contract research Organization: Cardiovascular Research Center - Sao Paulo, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CID - Carbostent &amp; Implantable Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of the Janus OPTIMA Tacrolimus-Eluting Stent (Optima TES,&#xD;
      CID) for the treatment of de novo coronary lesions when associated with short-term (two&#xD;
      months) dual antiplatelet (aspirin + clopidogrel) regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is a post-market, prospective, international, two-center, single arm study&#xD;
      involving 60 patients with single, de novo non-complex coronary lesions.&#xD;
&#xD;
      Enrolled patients will be asked to return for follow-up clinical evaluation at 1, 6, 12 and&#xD;
      24 months. At 3 months there will be an additional follow-up by phone contact.&#xD;
&#xD;
      Furthermore, the first 15 patients should undergo angiographic and OCT follow-up at two&#xD;
      months. The remaining 45 patients should undergo angiographic and IVUS follow-up at 8 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow inclusion, due to difficulties in obtaining the patients consent for the 2 months invasive&#xD;
    follow-up, as required by protocol design.&#xD;
  </why_stopped>
  <start_date type="Actual">October 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late lumen loss</measure>
    <time_frame>8-month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause and cardiac mortality;</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (MI): Q-wave and non-Q-wave, cumulative and individual</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (MACE) defined as a composite of cardiac death, MI (Q wave or non-Q wave), emergent coronary artery bypass surgery (CABG), or target lesion revascularization (TLR) by repeat PTCA or CABG</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of stent thrombosis using ARC definition of definite and probable stent thrombosis and categorized as early, late or very late</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent strut coverage assessed by OCT</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late acquired incomplete stent apposition by IVUS</measure>
    <time_frame>8-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In stent &amp; In segment angiographic parameters</measure>
    <time_frame>8-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Driven TLR</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Driven TVR</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF) defined as cardiac death, MI and ischemic Target Lesion Revascularization (TLR)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Stable Coronary Disease</condition>
  <condition>Unstable Coronary Disease</condition>
  <condition>Documented Silent Ischemia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug Eluting Stent</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with &gt;18 years of age;&#xD;
&#xD;
          -  Symptoms of stable or unstable angina and/or presence of a positive functional test&#xD;
             for ischemia;&#xD;
&#xD;
          -  Presence of a single de novo target lesion located in a native coronary vessel&#xD;
             suitable for percutaneous treatment with the study stents;&#xD;
&#xD;
          -  Acceptable candidate for coronary artery bypass graft(CABG)surgery;&#xD;
&#xD;
          -  The subject is willing to sign a written informed consent prior to procedure, and is&#xD;
             willing to undergo ALL study protocol follow-ups,including angiographic, IVUS and OCT&#xD;
             assessments.&#xD;
&#xD;
          -  Single, de novo lesion&#xD;
&#xD;
          -  Target lesion located in a major epicardial coronary vessel with reference of&#xD;
             2.5-3.5mm in diameter (by on-line QCA)&#xD;
&#xD;
          -  Target lesions ≤19mm in length (by visual estimation) that can be treated (covered) by&#xD;
             one single study stent (19 or 24mm in length);&#xD;
&#xD;
          -  ≥50% and &lt;100% diameter stenosis;&#xD;
&#xD;
          -  TIMI (Thrombolysis In Myocardial Infarction) flow grade ≥2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to tacrolimus, heparin,any required&#xD;
             medications including thienopyridines, and contrast media which cannot be adequately&#xD;
             pre medicated;&#xD;
&#xD;
          -  Patient is a female with childbearing potential;&#xD;
&#xD;
          -  Pre-treatment of the target lesion with any devices other than balloon angioplasty;&#xD;
&#xD;
          -  Previous brachytherapy in the target vessel;&#xD;
&#xD;
          -  Presence of non-target vessel lesions which require staged procedure(s) &lt;30 days of&#xD;
             the index procedure;&#xD;
&#xD;
          -  Prior CABG surgery to target vessel;&#xD;
&#xD;
          -  Previous percutaneous coronary intervention (PCI) or CABG surgery &lt;30 days to the&#xD;
             index procedure date;&#xD;
&#xD;
          -  Acute myocardial infarction &lt;3 days, with cardiac enzyme elevation including total&#xD;
             creatine kinase (CK) &gt;2 times the upper normal limit value and/or CK-MB above the&#xD;
             upper normal limit value within the past 72 hours;&#xD;
&#xD;
          -  CK and/or CK-MB levels elevated above the upper normal limit value at the time of the&#xD;
             index procedure;&#xD;
&#xD;
          -  Documented left ventricular ejection fraction &lt;30%;&#xD;
&#xD;
          -  Renal insufficiency determined by a baseline serum creatinine &gt;2.0 mg/dl;&#xD;
&#xD;
          -  Thrombocytopenia with a baseline platelet count &lt;100,000 cells/mm3;&#xD;
&#xD;
          -  Anemia with baseline hemoglobin &lt;10g/dL;&#xD;
&#xD;
          -  Extensive peripheral vascular disease or extreme anticoagulation that precludes safe&#xD;
             &gt;5 French sheath insertion;&#xD;
&#xD;
          -  History of bleeding diathesis, coagulopathy, or refusal of blood transfusions;&#xD;
&#xD;
          -  Patients has suffered a stroke, transient ischemic attack (TIA),or cerebrovascular&#xD;
             accident (CVA) within the past 6 months;&#xD;
&#xD;
          -  Significant gastrointestinal or genitourinary bleed within the past 6 months;&#xD;
&#xD;
          -  Patient is a recipient of a heart transplant;&#xD;
&#xD;
          -  Any elective surgical procedure is planned within 12 months of the index procedure;&#xD;
&#xD;
          -  Known illness or any serious clinical condition with life expectancy &lt;2 years;&#xD;
&#xD;
          -  Participation in the active or follow-up phase of any other clinicaltrial within 6&#xD;
             months;&#xD;
&#xD;
          -  Impossibility to comply with anti-platelet therapy during the study clinical&#xD;
             follow-up;&#xD;
&#xD;
          -  Any impossibility to comply with all protocol follow-ups.&#xD;
&#xD;
          -  Target lesion or vessel with angiographic evidence of moderate or severe&#xD;
             calcification;&#xD;
&#xD;
          -  Presence of severe tortuosity;&#xD;
&#xD;
          -  Presence of severe angulation (&gt;60o);&#xD;
&#xD;
          -  Presence of intraluminal thrombus;&#xD;
&#xD;
          -  Target lesion involving a bifurcation (side branch ≥2.0mm);&#xD;
&#xD;
          -  Target lesion located in the left main stem;&#xD;
&#xD;
          -  Aorto-ostial lesion location;&#xD;
&#xD;
          -  Target lesion involving a side branch with reference diameter≥2.0mm;&#xD;
&#xD;
          -  Presence of a significant stenosis (&gt;40%) in the target vessel either proximal or&#xD;
             distal to the target lesion that will be untreated;&#xD;
&#xD;
          -  Previous placement of a stent within 10mm of the target lesion;&#xD;
&#xD;
          -  Total occlusion (TIMI flow grade 0 or 1);&#xD;
&#xD;
          -  Target lesion located in an arterial or vein graft;&#xD;
&#xD;
          -  Target lesion due to in-stent restenosis;&#xD;
&#xD;
          -  Coronary anatomy unsuitable for percutaneous treatment with implantation of the&#xD;
             available study stents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Valgimigli, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero Universitaria di Ferrara - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre Abizaid, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Dante Pazzanese de Cardiologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Dante Pazzanesw</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 11, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Optima</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Drug eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

